|
|
Volumn 13, Issue 7, 2002, Pages 1140-1150
|
|
Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors
a
b
|
|
Author keywords
Pharmacokinetics; Phase I; Taxanes; Taxoid derivative
|
|
Indexed keywords
ANTIBIOTIC AGENT;
ANTIEMETIC AGENT;
ANTIHISTAMINIC AGENT;
CARBOPLATIN;
DEXAMETHASONE;
DOCETAXEL;
GRANULOCYTE COLONY STIMULATING FACTOR;
RPR 109881A;
STEROID;
TAXOID;
UNCLASSIFIED DRUG;
VINBLASTINE;
DRUG DERIVATIVE;
PACLITAXEL;
ADULT;
AGED;
ALOPECIA;
ANTINEOPLASTIC ACTIVITY;
ARTHRALGIA;
ARTICLE;
ASCITES;
BRAIN METASTASIS;
CANCER PATIENT;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIARRHEA;
DISTRIBUTION VOLUME;
DRUG BLOOD LEVEL;
DRUG CEREBROSPINAL FLUID LEVEL;
DRUG CLEARANCE;
DRUG DISTRIBUTION;
DRUG HALF LIFE;
DRUG HYPERSENSITIVITY;
DRUG INFUSION;
DRUG TOXICITY;
DRUG URINE LEVEL;
FATIGUE;
FEBRILE NEUTROPENIA;
FEMALE;
HUMAN;
LUNG NON SMALL CELL CANCER;
MALE;
MAXIMUM TOLERATED DOSE;
NEUROTOXICITY;
PHASE 1 CLINICAL TRIAL;
PLEURA EFFUSION;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SOLID TUMOR;
ADOLESCENT;
BIOAVAILABILITY;
CANCER STAGING;
COMPARATIVE STUDY;
DOSE RESPONSE;
DRUG ADMINISTRATION;
INTRAVENOUS DRUG ADMINISTRATION;
METABOLISM;
MIDDLE AGED;
MORTALITY;
NEEDLE BIOPSY;
NEOPLASM;
PATHOLOGY;
RISK ASSESSMENT;
SENSITIVITY AND SPECIFICITY;
SURVIVAL;
TREATMENT OUTCOME;
ADOLESCENT;
ADULT;
AGED;
BIOLOGICAL AVAILABILITY;
BIOPSY, NEEDLE;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
HUMANS;
INFUSIONS, INTRAVENOUS;
MALE;
MAXIMUM TOLERATED DOSE;
MIDDLE AGED;
NEOPLASM STAGING;
NEOPLASMS;
PACLITAXEL;
RISK ASSESSMENT;
SENSITIVITY AND SPECIFICITY;
SURVIVAL ANALYSIS;
TAXOIDS;
TREATMENT OUTCOME;
|
|
EID: 0035990845
PISSN: 09237534
EISSN: None
Source Type: Journal
DOI: 10.1093/annonc/mdf174 Document Type: Article |
|
Times cited : (44)
|
|
References (14)
|
